作者: 諂媚于人 時(shí)間: 2025-3-21 23:28 作者: BAIL 時(shí)間: 2025-3-22 03:18 作者: Affection 時(shí)間: 2025-3-22 06:11
Platforms for Recombinant Therapeutic Glycoprotein Production,in production, since glycosylation influences yield, pharmacokinetics, biological activity, and immunogenicity. This chapter covers the general aspects of therapeutic recombinant glycoproteins and the platforms that are being employed for their production.作者: 雀斑 時(shí)間: 2025-3-22 11:17
Purification Methods for Recombinant Factor VIII Expressed in Human Liver SK-Hep Cellsnity FVIII select and ion exchange SP-Fastflow chromatography steps without subjecting the target molecule to mechanical and temperature stress, separating impurities from rFVIII using net charge, hydrophobicity, and affinity of the molecules.作者: 捕鯨魚叉 時(shí)間: 2025-3-22 16:09 作者: 使?jié)M足 時(shí)間: 2025-3-22 20:30
Human Cells as Platform to Produce Gamma-Carboxylated Proteinsthe methods to generate human cells as a platform to produce gamma-carboxylated proteins, for example the coagulation factors VII and IX, are presented. From the cell line modification up to the vitamin K adaptation of the produced cells is described in the protocols presented in this chapter.作者: 背信 時(shí)間: 2025-3-22 22:35
Production of Recombinant Factor VIII in Human Cell Linesherefore, the production of recombinant factor VIII (rFVIII) in human cell lines is a new approach to avoid nonhuman glycosylation. Here, we describe a protocol to produce rFVIII in the human cell line SK-HEP, using a lentiviral vector to produce high quantities of the recombinant protein.作者: 嫻熟 時(shí)間: 2025-3-23 04:02
Strategies to Suspension Serum-Free Adaptation of Mammalian Cell Lines for Recombinant Glycoprotein s is challenging, time-consuming, and cell line and medium dependent. In this chapter, we present different approaches that can be used to adapt mammalian cell lines from an anchorage-dependent serum supplemented culture to a suspension serum-free culture.作者: 接合 時(shí)間: 2025-3-23 09:32 作者: UNT 時(shí)間: 2025-3-23 10:16
Strategies to Develop Therapeutic N- and O-Hyperglycosylated Proteins involves the initial stage of designing N- and/or O-hyperglycosylated muteins to be expressed by mammalian cells and includes the upstream and downstream processing stages necessary to develop hyperglycosylated versions of the proteins of interest with the purpose of beginning the long road toward producing biobetters.作者: 泥沼 時(shí)間: 2025-3-23 13:51 作者: 極少 時(shí)間: 2025-3-23 21:44
Microplate-Based Method for High-Throughput Screening (HTS) of Chromatographic Conditions Studies foimic chromatographic purification steps was established, several studies were performed successfully including scale down purification. Here, we propose a method for studying different purification conditions that can be used for any recombinant protein, including complex and glycosylated proteins, using low binding filter microplates.作者: FLIC 時(shí)間: 2025-3-24 00:19
Platforms for Recombinant Therapeutic Glycoprotein Production,es, with numerous products currently approved for clinical use. The choice of the expression system is a key step toward a successful functional protein production, since glycosylation influences yield, pharmacokinetics, biological activity, and immunogenicity. This chapter covers the general aspect作者: gentle 時(shí)間: 2025-3-24 03:24
Uncovering Innovation Features and Emerging Technologies in Molecular Biology through Patent Analyshnology for the development of their research, such as biotechnology, need to be aware of the frontier state-of-the-art technology and the knowledge incrusted within it. Although the information available in scientific articles is well explored in academic environment, the patent literature, where m作者: GEM 時(shí)間: 2025-3-24 07:25 作者: Locale 時(shí)間: 2025-3-24 10:51 作者: duplicate 時(shí)間: 2025-3-24 16:53
Production of Recombinant Factor VIII in Human Cell Linesential immunogenic reactions. Recombinant proteins produced in nonhuman cells can have in its structure glycan epitopes, such as Galα1,3-Gal (alpha-Gal) and N-glycolylneuraminic acid (Neu5Gc) residues, that are antigenic to humans and can potentially affect the efficacy of the recombinant product. T作者: Confess 時(shí)間: 2025-3-24 20:44 作者: 異常 時(shí)間: 2025-3-25 00:16
Production of Recombinant Rabies Virus Glycoprotein by Insect Cells in a Single-Use Fixed-Bed Bioreafor harvesting a membrane-associated viral glycoprotein with high quality in terms of preserved protein structure and biological function. Here, we describe the procedures for establishing genetically modified . Schneider 2 (S2) cell cultures in the iCELLis nano bioreactor and for quantifying by ELI作者: FRONT 時(shí)間: 2025-3-25 06:20 作者: 抗原 時(shí)間: 2025-3-25 10:27 作者: extrovert 時(shí)間: 2025-3-25 12:21 作者: 歌劇等 時(shí)間: 2025-3-25 15:55
Bioreactor-Based Production of Glycoproteins in Plant Cell Suspension Culturests in anticancer drugs. A specific glycan profile is often necessary to achieve certain desirable activities, such as the effector functions of an antibody, receptor binding or a sufficient serum half-life. However, many expression systems produce glycan profiles that differ substantially from the p作者: 誘拐 時(shí)間: 2025-3-25 22:00
Fed-Batch CHO Cell Culture for Lab-Scale Antibody Productionary (CHO) cells. Developing and optimizing this process in the lab is crucial for establishing process knowledge, which enables rapid and predictable tech-transfer to manufacturing scale. In this chapter, we describe stepwise how to carry out fed-batch CHO cell culture for lab-scale antibody product作者: 使糾纏 時(shí)間: 2025-3-26 03:20
Strategies to Develop Therapeutic N- and O-Hyperglycosylated Proteinsroteins with the aim of producing biotherapeutics with improved pharmacodynamic and pharmacokinetic properties. In this chapter, a detailed description of the steps routinely performed to generate new proteins having high content of N- and/or O-glycosyl moieties is carried out. The rational strategy作者: ANTIC 時(shí)間: 2025-3-26 04:24
Expression of Glycosylated Proteins in Bacterial System and Purification by Affinity Chromatographyvaccines against pathogens. In this case, a protein carrier conjugated with glycosides is used to produce intense stimulation of the immune system. Glycoconjugate vaccines account for 35% of the global vaccine market, and consequently, several biotechnological companies have developed products for t作者: Homocystinuria 時(shí)間: 2025-3-26 08:31
Purification Methods for Recombinant Factor VIII Expressed in Human Liver SK-Hep Cellsry short half-live and need a fast and efficient purification chain. Here, we describe a simple purification sequence using multimodal Capto MMC, affinity FVIII select and ion exchange SP-Fastflow chromatography steps without subjecting the target molecule to mechanical and temperature stress, separ作者: Gene408 時(shí)間: 2025-3-26 13:46 作者: 松軟無力 時(shí)間: 2025-3-26 18:35 作者: 鞭子 時(shí)間: 2025-3-26 21:27
Book 2018production. Chapters guide the reader through state-of-art of therapeutic recombinant glycoproteins, explores the patent literature, expression systems used for glycoproteins production, methods employed in the downstream processing of different glycoproteins, and information about analytical tools 作者: 才能 時(shí)間: 2025-3-27 02:45 作者: 美學(xué) 時(shí)間: 2025-3-27 07:00 作者: induct 時(shí)間: 2025-3-27 13:26
Recombinant Glycoprotein Production978-1-4939-7312-5Series ISSN 1064-3745 Series E-ISSN 1940-6029 作者: 撫育 時(shí)間: 2025-3-27 15:23 作者: fiction 時(shí)間: 2025-3-27 21:01
https://doi.org/10.1007/978-1-4939-7312-5Glycoengineering; Glycosylation; viral-particles; gene therapy; bifunctional antibodies作者: 結(jié)構(gòu) 時(shí)間: 2025-3-27 23:44
Fed-Batch CHO Cell Culture for Lab-Scale Antibody Productionary (CHO) cells. Developing and optimizing this process in the lab is crucial for establishing process knowledge, which enables rapid and predictable tech-transfer to manufacturing scale. In this chapter, we describe stepwise how to carry out fed-batch CHO cell culture for lab-scale antibody production.作者: Nefarious 時(shí)間: 2025-3-28 03:48
Purification Method for Recombinant hG-CSF by Affinity Chromatography chemotactic activity. It has been used in the treatment of many diseases, in particular in neutropenic conditions. Here, we describe the purification process of the recombinant protein hG-CSF expressed in .. The protein purification proved to be efficient using the nickel affinity chromatography method described in this chapter.作者: heterodox 時(shí)間: 2025-3-28 07:46
Yuzhou Fan,Daniel Ley,Mikael R?rdam Andersenitionally, this mission has been categorised in NASA Solar System Exploration Committee’s augmented programme as a mission of high scientific merit. The Rosetta mission constitutes the next logical step in cometary exploration after fly-by and rendez-vous missions. It can be regarded as one of the m作者: 光亮 時(shí)間: 2025-3-28 14:04
xample is often used in traditional thermodynamics text books to demonstrate that an arbitrarily slow process need not be reversible. Cyclic operation of any engine that involves a free expansion is therefore necessary dissipative. Here, we explore experimentally the origin of the thermodynamic irre作者: 協(xié)議 時(shí)間: 2025-3-28 18:15 作者: Spinal-Fusion 時(shí)間: 2025-3-28 20:02
Bruna Samham Archangelo,Elisa Maria de Sousa Russoly distinguished by having specific performance characteristics which are optimised for use in particular kinds of application. In order to simplify experimental procedure the circuits given in the book all use the same amplifier type, the 741. This type was chosen for its ready availability, for th作者: 消毒 時(shí)間: 2025-3-28 23:52
Rimenys J. Carvalho,Thayana A. Cruzly distinguished by having specific performance characteristics which are optimised for use in particular kinds of application. In order to simplify experimental procedure the circuits given in the book all use the same amplifier type, the 741. This type was chosen for its ready availability, for th作者: 虛弱的神經(jīng) 時(shí)間: 2025-3-29 04:24
Amanda Mizukami,Angelo Luis Caron,Virgínia Pican?o-Castro,Kamilla Swiech作者: 慢慢流出 時(shí)間: 2025-3-29 10:00
Cristiano Gon?alves Pereira,Geciane Silveira Porto作者: Musculoskeletal 時(shí)間: 2025-3-29 14:18
Aline de Sousa Bomfim,Marcela Cristina Corrêa de Freitas,Dimas Tadeu Covas,Elisa Maria de Sousa Russ作者: 600 時(shí)間: 2025-3-29 15:57
Daianne Maciely Carvalho Fantacini,Virgínia Pican?o-Castro作者: 佛刊 時(shí)間: 2025-3-29 22:00 作者: STAT 時(shí)間: 2025-3-30 03:41
Daniella C. Ventini-Monteiro,Renato M. Astray,Carlos A. Pereira作者: Indurate 時(shí)間: 2025-3-30 04:35 作者: 大火 時(shí)間: 2025-3-30 08:45
Agustina Gugliotta,Natalia Ceaglio,Marina Etcheverrigaray,Ricardo Kratje,Marcos Oggero作者: 欲望小妹 時(shí)間: 2025-3-30 13:21
Carlos Alexandre Breyer,Marcos Antonio de Oliveira,Adalberto Pessoa Jr作者: Maximizer 時(shí)間: 2025-3-30 18:30 作者: 誤傳 時(shí)間: 2025-3-30 22:46 作者: 不公開 時(shí)間: 2025-3-31 03:08 作者: 雜役 時(shí)間: 2025-3-31 06:32 作者: Boycott 時(shí)間: 2025-3-31 11:13
1064-3745 ips on troubleshooting and avoiding known pitfalls.. .Authoritative and cutting-edge, .Recombinant Glycoprotein Production: Methods and Protocols?.aims to ensure successful results in the further study of this vital field.978-1-4939-8449-7978-1-4939-7312-5Series ISSN 1064-3745 Series E-ISSN 1940-6029 作者: 侵略 時(shí)間: 2025-3-31 14:29 作者: 事物的方面 時(shí)間: 2025-3-31 17:38
k, while the other required work, no matter how slowly it was carried out. A statistical analysis and a recently derived formula are used to show that the difference traces back to the observation that when time is reversed the two protocols have different outcomes. This property is not possible to 作者: 未開化 時(shí)間: 2025-4-1 01:15
